Hybrid Positron Emission Tomography-magnetic Resonance Imaging for Assessing Different Stages of Cardiac Impairment in Patients with Anderson-Fabry Disease: AFFINITY Study Group
Overview
Radiology
Authors
Affiliations
Aims: Anderson-Fabry disease (AFD) is an X-linked lysosomal storage disorder associated with multi-organ dysfunction. While native myocardial T1 mapping by magnetic resonance (MR) allow non-invasive measurement of myocyte sphingolipid accumulation, 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and MR are able to identify different pathological patterns of disease progression. We investigated the relationship between T1 mapping and 18F-FDG uptake by hybrid PET-MR cardiac imaging in AFD female patients.
Methods And Results: Twenty AFD females without cardiac symptoms underwent cardiac PET-MR using 18F-FDG for glucose uptake. In all patients and in seven age- and sex-matched control subjects, T1 mapping was performed using native T1 Modified Look-Locker Inversion-recovery prototype sequences. 18F-FDG myocardial uptake was quantified by measuring the coefficient of variation (COV) of the standardized uptake value using a 17-segment model. T1 values of AFD patients were lower compared with control subjects (1236 ± 49 ms vs. 1334 ± 27 ms, P < 0.0001). Focal 18F-FDG uptake with COV >0.17 was detected in seven patients. COV was 0.32 ± 0.1 in patients with focal 18F-FDG uptake and 0.12 ± 0.04 in those without (P < 0.001). Patients with COV >0.17 had higher T1 values of lateral segments of the mid ventricular wall, compared with those with COV ≤0.17 (1216 ± 22 ms vs. 1160 ± 59 ms, P < 0.05).
Conclusion: In females with AFD, focal 18F-FDG uptake with a trend towards a pseudo-normalization of abnormal T1 mapping values, may represent an intermediate stage before the development of myocardial fibrosis. These findings suggest a potential relationship between progressive myocyte sphingolipid accumulation and inflammation.
Contemporary Multimodality Imaging for Diagnosis and Management of Fabry Cardiomyopathy.
Kaur S, Bhalla J, Erwin A, Jaber W, Wang T J Clin Med. 2024; 13(16).
PMID: 39200913 PMC: 11355474. DOI: 10.3390/jcm13164771.
Arrhythmogenesis in Fabry Disease.
Roy A, Cumberland M, OShea C, Holmes A, Kalla M, Gehmlich K Curr Cardiol Rep. 2024; 26(6):545-560.
PMID: 38607539 PMC: 11199244. DOI: 10.1007/s11886-024-02053-2.
Advanced CMR Techniques in Anderson-Fabry Disease: State of the Art.
Ponsiglione A, De Giorgi M, Ascione R, Nappi C, Sanduzzi L, Pisani A Diagnostics (Basel). 2023; 13(15).
PMID: 37568960 PMC: 10417643. DOI: 10.3390/diagnostics13152598.
Inflammatory Fabry Cardiomyopathy Demonstrated Using Simultaneous [F]-FDG PET-CMR.
Orsborne C, Anton-Rodrigez J, Sherratt N, Watkins A, Lohezic M, Clark D JACC Case Rep. 2023; 15:101863.
PMID: 37283843 PMC: 10240277. DOI: 10.1016/j.jaccas.2023.101863.
Gatterer C, Wollenweber T, Pichler V, Vraka C, Sunder-Plassmann G, Lenz M J Nucl Cardiol. 2023; 30(5):1810-1821.
PMID: 36855009 PMC: 10558396. DOI: 10.1007/s12350-023-03205-7.